ADVANCED GLAUCOMA INTERVENTION STUDY COORDINATING CENTER

这是对协调中心5年支持的申请 在埃默斯公司继续参与正在进行的 多中心晚期青光眼干预研究(AGIS)。 AGIS的主要目标是系统地评估 原发性开角眼的序贯干预效果分析 初次治疗失败的青光眼。在4月1日之间， 1988年和1991年3月31日，AGIS收治了435名患者575只眼。每个人 眼睛被随机分配到以下两种干预序列之一：1) 小梁切除术(T)后行激光小梁成形术(ALT) 失败，如果ALT失败，则紧跟第二个T；以及2)ALT和T 如果ALT失败，则在第一个T失败的情况下跟随另一个T。这个 根据需要进行干预并辅之以医疗治疗。自.起 1991年3月31日随访0~36个月。不到五个 计划每6个月进行一次的后续检查的百分比 打偏了。正在收集有关视觉功能丧失、干预的数据 失败、并发症、需要补充药物治疗、依从性 用药物治疗，并提高生活质量。高血压性脑脊髓炎的预后价值 眼科和非眼科的医疗因素和个人因素 学习。这项研究计划1)继续招募病人，直到790 Eyes已经注册，这一目标预计将在4月1日之间实现 和1992年11月30日，以及2)继续患者随访，直到 1996年11月30日，因此后续行动最终将从最低限度 4至4 2/3年至最长8 2/3年。协调中心 提供数据管理、统计和运营支持 学习。政策和治疗效果监测委员会监督 进行研究并监测研究结果。已与 乔治城大学的主要应用有：1)AGIS研究计划， 详细说明研究的理论基础、设计和方法，2)计划 持续的患者招募和随访，以及3)研究成果 迄今为止，包括数据分析的例子。本申请 详细说明了协调中心继续的资格 参与，包括描述我们迄今取得的成就。

This is an application for 5 years of support for the coordinating center at The EMMES Corporation to continue participation in the ongoing multicenter Advanced Glaucoma Intervention Study (AGIS). The principal goal of AGIS is to assess systematically the long-range outcomes of sequences of interventions in eyes with primary open-angle glaucoma that have failed initial medical treatment. Between April 1, 1988 and March 31, 1991 AGIS has enrolled 575 eyes of 435 patients. Each eye has been randomly assigned to one of two intervention sequences: 1) trabeculectomy (T) followed by argon laser trabeculoplasty (ALT) should T fail and followed by a second T should ALT fail; and 2) ALT followed by T should ALT fail and followed by another T should the first T fail. The interventions are supplemented with medical treatment as needed. As of March 31, 1991 follow-up ranged from 0 to 36 months. Less than five percent of follow-up exams, scheduled at 6-month intervals, have been missed. Data are being collected on visual function loss, intervention failure, complications, need for supplemental medical therapy, compliance with medical therapy, and quality of life. The prognostic value of ocular and non-ocular medical factors and personal factors are being studied. The study plans 1) to continue patient recruitment until 790 eyes are enrolled, a goal that is expected to be reached between April 1 and November 30, 1992, and 2) to continue patient follow-up until November 30, 1996, so that follow-up will ultimately range from a minimum of 4 to 4 2/3 years to a maximum of 8 2/3 years. The coordinating center provides data management, statistical, and operational support to the study. A Policy and Treatment Effects Monitoring Board supervises the conduct of the study and monitors study outcomes. Submitted with the Georgetown University lead application are: 1) the AGIS research plan, detailing study rationale, design, and methods, 2) the plans for continued patient recruitment and follow-up, and 3) study accomplishments to date, including examples of data analyses. The present application details the qualifications of the coordinating center for continued participation, including a description of our accomplishments to date.